G25.71 Drug induced akathisia

Name of the Condition

• Drug Induced Akathisia
• ICD-10 Code: G25.71

Summary

Drug induced akathisia is a movement disorder characterized by an inability to remain still, often resulting from medication use. It involves a subjective sense of restlessness and an objective need to move, typically affecting the legs but potentially involving other body parts. The condition arises as a side effect of certain drugs and can significantly impact quality of life.

Causes

Akathisia is caused by medications that interfere with dopamine neurotransmission in the brain. Drugs such as antipsychotics, antiemetics, and some antidepressants are common culprits. The exact mechanism involves disruption of the basal ganglia's motor control pathways, leading to the characteristic restlessness.

Risk Factors

• Use of medications known to affect dopamine levels
• High doses or rapid dose increases of such drugs
• Pre-existing neurological vulnerabilities
• Advanced age, which may increase susceptibility to side effects

Symptoms

• Subjective feeling of inner restlessness or agitation
• Inability to remain seated or still
• Pacing, fidgeting, or constant movement of the legs
• Distress or discomfort due to the inability to rest
• Agitation or irritability

Diagnosis

Diagnosis is primarily clinical, based on symptom history and a review of medication use. A physical examination assesses movement patterns, and clinicians rule out other causes of restlessness, such as anxiety or other movement disorders. Documentation of symptom onset relative to medication initiation is critical.

Treatment Options

• Discontinuation or dose reduction of the offending medication
• Use of medications like beta-blockers or benzodiazepines to manage symptoms
• Switching to alternative therapies with lower akathisia risk
• Supportive care to address distress and agitation

Prognosis and Follow-Up

Prognosis is generally favorable with appropriate intervention, as symptoms often resolve once the causative drug is adjusted or discontinued. Follow-up is necessary to monitor symptom resolution and adjust treatment as needed. Persistent cases may require ongoing management to prevent recurrence.

Complications

• Worsening of psychiatric symptoms if medication is discontinued abruptly
• Increased risk of falls or accidents due to restlessness
• Emotional distress or agitation leading to functional impairment
• Potential for misdiagnosis as anxiety or agitation

Lifestyle & Prevention

• Regular monitoring of medication side effects
• Gradual dose adjustments under medical supervision
• Avoidance of abrupt changes to drug regimens
• Patient education on recognizing early signs of akathisia

When to Seek Professional Help

Seek medical attention if restlessness or inability to remain still develops after starting a new medication. Prompt evaluation is important to identify the cause and adjust treatment to prevent worsening symptoms or complications.

Tips for Medical Coders

When coding G25.71, ensure documentation clearly links the akathisia to a specific drug or class of drugs. Note the onset, duration, and severity of symptoms, as well as any interventions or adjustments to medication. Differentiate from other movement disorders or psychiatric conditions to support accurate coding.